Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans

The immunologic basis for the potential enhanced HIV-1 acquisition in Ad5 seropositive individuals who received the Merck rAd5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Kara L., Liu, Jinyan, King, Sharon L., Sun, Ying-Hua, Schmitz, Joern E., Lifton, Michelle A., Hutnick, Natalie A., Betts, Michael R., Dubey, Sheri A., Goudsmit, Jaap, Shiver, John W., Robertson, Michael N., Casimiro, Danilo R., Barouch, Dan H.
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756115/
https://www.ncbi.nlm.nih.gov/pubmed/19620961
http://dx.doi.org/10.1038/nm.1991
Descripción
Sumario:The immunologic basis for the potential enhanced HIV-1 acquisition in Ad5 seropositive individuals who received the Merck rAd5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5 seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5 seronegative subjects following vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.

Ejemplares similares